Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions.
Since its clinical introduction, the anaphylactic potential of aprotinin has been a major concern. World wide, its use is expanding so there is an increased chance that patients have reexposure from various sources. The risk of anaphylaxis is approximately 2.8% in reexposed patients. From 1963 to 2003, 124 cases of aprotinin-induced anaphylaxis were reported in 61 publications. Eleven patients died. The reexposure interval was less than 3 months in 72% (38 of 53 patients). This review looks at the profile of patients at risk so preventive measures may be taken. Past and future exposures have to be taken into account before any aprotinin administration.
Beierlein
Wolfram
W
Department of Thoracic, Cardiac, and Vascular Surgery, Tübingen University Hospital, Tübingen, Germany. wolfram.beierlein@t-online.de
Scheule
Albertus M
AM
Dietrich
Wulf
W
Ziemer
Gerhard
G
D007611:Aprotinin / Q000009:adverse effects*; D006348:Cardiac Surgical Procedures / Q000379:methods / Q000706:statistics & numerical data; D004342:Drug Hypersensitivity / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology* / Q000517:prevention & control; D004363:Drug Utilization / Q000706:statistics & numerical data; D006632:Histamine; D006801:Humans; D012698:Serologic Tests; D015996:Survival Rate
D006632:Histamine; D007611:Aprotinin